Natus Medical Incorporated (BABY) Given Average Recommendation of “Hold” by Analysts
Shares of Natus Medical Incorporated (NASDAQ:BABY) have been assigned an average recommendation of “Hold” from the seven analysts that are currently covering the stock, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell rating, three have assigned a hold rating and one has issued a buy rating on the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $48.00.
A number of research firms recently commented on BABY. BidaskClub cut Natus Medical from a “hold” rating to a “sell” rating in a report on Tuesday, August 1st. Zacks Investment Research raised Natus Medical from a “sell” rating to a “hold” rating in a report on Friday, September 22nd.
In other news, Director William M. Moore sold 3,000 shares of the company’s stock in a transaction that occurred on Monday, August 14th. The stock was sold at an average price of $34.10, for a total transaction of $102,300.00. Following the sale, the director now directly owns 30,410 shares of the company’s stock, valued at approximately $1,036,981. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Robert A. Gunst sold 4,400 shares of the company’s stock in a transaction that occurred on Thursday, September 14th. The stock was sold at an average price of $35.17, for a total value of $154,748.00. Following the sale, the director now directly owns 50,850 shares in the company, valued at $1,788,394.50. The disclosure for this sale can be found here. 5.50% of the stock is currently owned by insiders.
Institutional investors and hedge funds have recently modified their holdings of the company. Riverhead Capital Management LLC raised its holdings in shares of Natus Medical by 90.9% during the 2nd quarter. Riverhead Capital Management LLC now owns 2,864 shares of the medical equipment provider’s stock worth $107,000 after acquiring an additional 1,364 shares in the last quarter. Ameritas Investment Partners Inc. bought a new position in shares of Natus Medical during the 1st quarter valued at approximately $110,000. Sei Investments Co. increased its position in shares of Natus Medical by 29.7% during the 2nd quarter. Sei Investments Co. now owns 3,182 shares of the medical equipment provider’s stock valued at $119,000 after purchasing an additional 728 shares during the last quarter. Victory Capital Management Inc. increased its position in shares of Natus Medical by 94.0% during the 1st quarter. Victory Capital Management Inc. now owns 3,184 shares of the medical equipment provider’s stock valued at $125,000 after purchasing an additional 1,543 shares during the last quarter. Finally, Flinton Capital Management LLC increased its position in shares of Natus Medical by 82.0% during the 2nd quarter. Flinton Capital Management LLC now owns 3,774 shares of the medical equipment provider’s stock valued at $141,000 after purchasing an additional 1,700 shares during the last quarter. 92.66% of the stock is currently owned by institutional investors and hedge funds.
Natus Medical (BABY) traded up 0.37% on Wednesday, hitting $40.30. 410,765 shares of the company traded hands. The firm’s 50 day moving average price is $35.76 and its 200 day moving average price is $36.05. The firm has a market capitalization of $1.31 billion, a PE ratio of 69.84 and a beta of 0.95. Natus Medical has a 1-year low of $31.65 and a 1-year high of $43.85.
Natus Medical (NASDAQ:BABY) last posted its quarterly earnings results on Wednesday, July 26th. The medical equipment provider reported $0.34 EPS for the quarter, topping the Zacks’ consensus estimate of $0.33 by $0.01. Natus Medical had a return on equity of 12.09% and a net margin of 4.20%. The company had revenue of $122.20 million for the quarter, compared to analysts’ expectations of $121.99 million. During the same period in the previous year, the firm earned $0.39 EPS. The firm’s revenue was up 27.3% compared to the same quarter last year. Equities research analysts predict that Natus Medical will post $1.70 EPS for the current fiscal year.
Natus Medical Company Profile
Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.
Receive News & Ratings for Natus Medical Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.